Ibandronic Acid Accord Healthcare Ireland

Active Ingredient:: Ibandronic Acid
Origin:: EU

Ibandronic Acid Accord Healthcare Ireland (Ibandronic Acid)

Q: What is Ibandronic Acid used for?

Ibandronic Acid is an oral bisphosphonate prescribed to treat osteoporosis in post‑menopausal women, men, and patients receiving long‑term glucocorticoids. It works by reducing bone loss, thereby lowering the risk of vertebral and hip fractures.

Q: How does Ibandronic Acid work?

The drug binds to bone mineral at sites of active remodeling and is taken up by osteoclasts. Inside these cells it inhibits the enzyme farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and suppressing osteoclast‑mediated bone resorption.

Q: What is the usual dose of Ibandronic Acid?

The dosing regimen for Ibandronic Acid is determined by the prescribing clinician based on the patient’s condition, renal function, and other clinical factors. Patients should follow the specific instructions provided by their healthcare professional.

Q: Is Ibandronic Acid safe during pregnancy or breastfeeding?

Safety data for Ibandronic Acid in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

Q: How do I order Ibandronic Acid from GNH India?

To request Ibandronic Acid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Ibandronic Acid compare with other osteoporosis treatments?

Ibandronic Acid is a once‑monthly oral bisphosphonate, offering a convenient dosing schedule compared with daily or weekly alternatives. Its efficacy in increasing bone mineral density and reducing fracture risk is comparable to other bisphosphonates, while its safety profile reflects the class‑related gastrointestinal and rare bone‑related risks.

Q: How should Ibandronic Acid be stored and handled?

Store the tablets at room temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Q: How is Ibandronic Acid administered?

Ibandronic Acid is taken orally with a full glass of plain water on an empty stomach, preferably first thing in the morning. Patients should remain upright for at least 30 minutes and avoid eating, drinking, or taking other medications during that time.

Q: What are the most serious risks associated with Ibandronic Acid?

Serious but rare risks include osteonecrosis of the jaw, atypical femur fractures, severe hypersensitivity reactions, and esophageal ulceration. Patients should report persistent jaw pain, unusual thigh pain, or any signs of an allergic reaction to their healthcare provider promptly.

Q: Who should not use Ibandronic Acid?

Ibandronic Acid is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to ibandronate or other bisphosphonates, and those with esophageal disorders that delay tablet passage. Clinicians should also avoid use in patients unable to sit or stand upright for at least 30 minutes after dosing.

Ibandronic Acid, the active ingredient in Ibandronic Acid Accord Healthcare Ireland, is a bisphosphonate presented as an oral tablet for oral use. It treats osteoporosis in post‑menopausal women, men and patients receiving glucocorticoid therapy.
GNH India supplies Ibandronic Acid Accord Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Accord Healthcare Ireland Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ibandronic Acid is a bisphosphonate used to manage conditions characterised by increased bone resorption.

Postmenopausal osteoporosis: improves bone mineral density and lowers the risk of vertebral and hip fractures.
Male osteoporosis: improves bone mineral density and lowers the risk of fractures.
Glucocorticoid‑induced osteoporosis: helps maintain bone density during long‑term steroid therapy.

How It Works

Ibandronic Acid binds selectively to hydroxyapatite crystals at sites of active bone remodeling. When osteoclasts attach to the bone surface, the drug is internalised, inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway. This disrupts prenylation of small G‑proteins, leading to reduced osteoclast activity, decreased bone resorption, and a net increase in bone mineral density.

Side Effects

Ibandronic Acid may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

Nausea: mild to moderate stomach upset after dosing.
Abdominal pain: discomfort in the upper abdomen.
Dyspepsia: indigestion or heartburn.
Constipation: reduced bowel movements.
Musculoskeletal pain: aches in muscles or joints.
Headache: transient head discomfort.

Serious or Rare Side Effects

Osteonecrosis of the jaw: persistent exposed bone in the oral cavity.
Atypical femur fracture: unusual break in the thigh bone.
Severe hypersensitivity: rash, swelling, or anaphylaxis.
Acute‑phase reaction: fever, myalgia, or flu‑like symptoms shortly after the first dose.
Esophageal ulceration or erosion: pain or difficulty swallowing.

Precautions & Warnings

Before prescribing Ibandronic Acid, clinicians should consider several safety measures.

Assess renal function: avoid use in patients with severe renal impairment (creatinine clearance <30 mL/min).
Review calcium/vitamin D status: ensure adequate supplementation to support bone health.
Avoid concomitant oral bisphosphonates: combined therapy may increase oversuppression of bone turnover.
Monitor for esophageal disorders: advise patients to remain upright for at least 30 minutes after taking the tablet.
Educate on proper administration: swallow with a full glass of water and do not lie down immediately.
Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Ibandronic Acid can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

Other bisphosphonates: additive suppression of bone remodeling may increase fracture risk.
Calcium or multivitamin supplements taken within 2 hours of the dose: markedly reduces drug absorption.
NSAIDs or systemic corticosteroids: heightened risk of gastrointestinal irritation.

Moderate Interactions (Monitor Closely)

Antacids containing aluminum or magnesium: may lower oral bioavailability; separate dosing by at least 2 hours.
Proton‑pump inhibitors: altered gastric pH can affect absorption; monitor therapeutic response.
Warfarin: potential increase in INR; regular coagulation monitoring is advised.

Frequently Asked Questions

Ibandronic Acid is an oral bisphosphonate prescribed to treat osteoporosis in post‑menopausal women, men, and patients receiving long‑term glucocorticoids. It works by reducing bone loss, thereby lowering the risk of vertebral and hip fractures.

The drug binds to bone mineral at sites of active remodeling and is taken up by osteoclasts. Inside these cells it inhibits the enzyme farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and suppressing osteoclast‑mediated bone resorption.

The dosing regimen for Ibandronic Acid is determined by the prescribing clinician based on the patient’s condition, renal function, and other clinical factors. Patients should follow the specific instructions provided by their healthcare professional.

Safety data for Ibandronic Acid in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Ibandronic Acid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ibandronic Acid is a once‑monthly oral bisphosphonate, offering a convenient dosing schedule compared with daily or weekly alternatives. Its efficacy in increasing bone mineral density and reducing fracture risk is comparable to other bisphosphonates, while its safety profile reflects the class‑related gastrointestinal and rare bone‑related risks.

Store the tablets at room temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Ibandronic Acid is taken orally with a full glass of plain water on an empty stomach, preferably first thing in the morning. Patients should remain upright for at least 30 minutes and avoid eating, drinking, or taking other medications during that time.

Serious but rare risks include osteonecrosis of the jaw, atypical femur fractures, severe hypersensitivity reactions, and esophageal ulceration. Patients should report persistent jaw pain, unusual thigh pain, or any signs of an allergic reaction to their healthcare provider promptly.

Ibandronic Acid is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to ibandronate or other bisphosphonates, and those with esophageal disorders that delay tablet passage. Clinicians should also avoid use in patients unable to sit or stand upright for at least 30 minutes after dosing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 31 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.